Title : RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.

Pub. Date : 2018 Jul 3

PMID : 30038711






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. ponatinib ret proto-oncogene Homo sapiens
2 Identifying ponatinib as the most potent RET inhibitor tested, we used ponatinib to gauge therapeutic responsiveness in RET fusion-positive patient-derived xenograft (PDX) models. ponatinib ret proto-oncogene Homo sapiens
3 By comparing ponatinib activity in RET fusion-positive and RET fusion-negative PDX models alongside a standard of care chemotherapeutic agent, we show that RET fusions in colorectal tumors are therapeutically responsive to RET inhibition. ponatinib ret proto-oncogene Homo sapiens